Esophageal candidiasis secondary prevention

Esophageal candidiasis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Esophageal candidiasis from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Esophageal candidiasis secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Esophageal candidiasis secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Esophageal candidiasis secondary prevention
CDC on Esophageal candidiasis secondary prevention
Esophageal candidiasis secondary prevention in the news
Blogs on Esophageal candidiasis secondary prevention
Directions to Hospitals Treating Esophageal candidiasis
Risk calculators and risk factors for Esophageal candidiasis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Ahmed Younes M.B.B.CH [2]

Overview

Secondary prevention strategies following esophageal candidiasis in HIV patients include prophylactic fluconazole therapy.

Secondary prevention

• Secondary prevention strategies following esophageal candidiasis in HIV patients include prophylactic fluconazole therapy in a dose of 100-200 mg repeated 3 times/week.
• It has bben proven to decrease recurrence of esophageal candidiasis.